Shares of Zydus Lifesciences slipped 0.7% to ₹1,131 on the BSE, ending the session lower by ₹8.00. Despite the dip, the firm posted a 22% jump in revenue to ₹8,017 crore, up from ₹6,573 crore a year earlier.
EBITA declined 7.6% year‑on‑year, falling to ₹1,929.4 crore from ₹2,088.5 crore, and the operating margin contracted to 24.1% from 31.8% in the previous fiscal. Analysts had expected a 27% revenue rise and a margin of 26%, so the beat on sales was offset by a weaker bottom line.
North‑American formulations sales were down 2.6% YoY, registering ₹3,098 crore, yet they grew 4.9% sequentially, driven by new product launches and volume expansion. International markets continued to support growth, with the consumer wellness and MedTech segments maintaining market dominance.
The U.S. Food and Drug Administration completed a routine inspection of the Moraiya plant between Oct 5‑13, 2026, raising five observations. Zydus said it would collaborate closely with the FDA to resolve the points quickly, but the findings did not trigger a significant market reaction.
Looking ahead, Zydus will report its Q2 results on Nov 15 and is maintaining a cautious stance on guidance. The company plans to extend its Sterling Biotech API acquisition deadline to Sept 30, signalling ongoing expansion plans while managing regulatory compliance.